You are here

Canadian Nuclear Laboratories and TRIUMF to Host 11th Targeted-Alpha-Therapy Symposium

Canadian Nuclear Laboratories and TRIUMF to Host 11th Targeted-Alpha-Therapy Symposium

29 January 2018

CHALK RIVER, Ontario and VANCOUVER, British Columbia, Jan. 29, 2018 -- Canadian Nuclear Laboratories (CNL), Canada’s premier nuclear science and technology organization, and TRIUMF jointly announced today that they are partnering to co-host the 11th Targeted-Alpha-Therapy Symposium (TAT11) to be held from April 1 – 5, 2019 at the Fairmont Château Laurier in Ottawa.

TAT11 is a global forum for academic and industry leaders to meet and discuss the latest technical, regulatory and clinical developments in targeted radiopharmaceutical therapy. The potential benefits of targeted-alpha-therapy in the battle against cancer and other diseases are significant. While existing radiation treatments target all cells in the vicinity of a tumor, both healthy and cancerous, targeted-alpha-therapy focuses the treatment application to cancerous or unhealthy cells. This limits the overall radiation dose a patient may receive, holds promise of better patient outcomes, and encourages a faster recovery time following treatment.

In addition to a variety of industry and academic speakers and presentations, the TAT11 conference will feature an exhibition for companies to showcase their products and services and will include a tour of the Chalk River Laboratories.